Corbus Pharmaceuticals Holdings (CRBP) Retained Earnings (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Retained Earnings for 13 years, with the latest figure at $703.0 million in Q4 2025.

• On a quarterly basis, Retained Earnings rose 13.52% year-over-year to $703.0 million in Q4 2025; TTM through Dec 2025 was $703.0 million, a 13.52% increase from a year earlier, with the FY2025 full-year figure at $703.0 million, up 13.52% from the prior year.
• Retained Earnings was $703.0 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $627.0 million in the prior quarter.
• The five-year high for Retained Earnings was $703.0 million in Q4 2025, with the low at -$436.7 million in Q4 2023.
• Average Retained Earnings over 5 years is $456.5 million, with a median of $427.3 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings tumbled 202.7% in 2023, then surged 241.82% in 2024.
• Over 5 years, Retained Earnings stood at $418.9 million in 2021, then gained by 1.5% to $425.2 million in 2022, then sank by 202.7% to -$436.7 million in 2023, then soared by 241.82% to $619.3 million in 2024, then increased by 13.52% to $703.0 million in 2025.
• The last three Retained Earnings figures came in at $703.0 million (Q4 2025), $627.0 million (Q3 2025), and $622.6 million (Q2 2025), per Business Quant data.